Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 09, 2022 at 04:01 pm EDT
Share
Y-mAbs Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 10.49 million compared to USD 5.38 million a year ago. Net loss was USD 28.07 million compared to net income of USD 33.41 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to basic earnings per share from continuing operations of USD 0.8 a year ago. Diluted loss per share from continuing operations was USD 0.64 compared to diluted earnings per share from continuing operations of USD 0.75 a year ago.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.